Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Int J Oncol. 2009 Aug;35(2):229-38.

The 'timely' development of Rexin-G: first targeted injectable gene vector (review).

Author information

  • 1Epeius Biotechnologies Corporation, San Marino, CA 91108, USA. egordon@epeiusbiotech.com


In an age where we can i) know precisely where a misplaced automobile resides by its global positioning, ii) send mechanistic probes to Mars with pinpoint accuracy, iii) calculate exactly how many mutations are required to create (i.e., to transform) a cancer cell, and iv) determine how many fewer genes it takes to develop a human being than it does a rice plant, it is difficult to fathom the previously unanswered question: 'Whatever happened to the promise and potential of cancer gene therapy?' This review answers that question with a resounding clinical dénouement. In addition, it provides a 'Cooks tour' of applied molecular genetics and nanotechnology as these fields relate to the development of Rexin-G the world's first tumor-targeted genetic medicine to be fully validated in the clinic. The commentary will expose certain fallacies and ideologies that have retarded the progress of cancer gene therapy as it advances our instruments and understanding of the finespun fabric of our nature.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Spandidos Publications
    Loading ...
    Write to the Help Desk